Table 6.

Liver Perfusion Parameters and Proposed Viability Criteria

	Non‐LC						LC
Liver number	1	2	3	4	5	6	1 *	2	3	4	5	6 *
Perfusion time (minutes)	541	192	501	1102	738	394	393	277	378	403	388	316
Lactate T0 (mmol/L)	>20.0	13.4	13.0	13.3	7.2	15.2	7.6	9.4	12.9	13.9	13.9	5.5
Lactate T2 (mmol/L)	19.2	16.4	20.0	12.5	4.4	15.1	1.2	4.6	0.6	5.5	3.2	3.0
Trough lactate (mmol/L)	12.8	13.4	13.0	8.8	4.4	6.9	0.7	2.1	0.6	1.2	0.8	1.4
Bile production T6 (grams)	0.0	0.0	0.0	0.0	2.6	0.0	23.0	6.1	10.4	0.0	6.9	0
ATP T0 (nmol/g protein) †	15.8	—	12.1	0.0	24.6	74.7	—	—	54.6	88.1	0.0	—
ATP T6 (nmol/g protein) †	46.6	—	0.6	11.5	11.9	512.8	—	—	334.6	1001.9	93.5	—
ALT (IU/L)† T0	—	—	4055	—	—	2888	—	—	574	—	2603	3673
ALT (IU/L)† peak value			—			5017			1498	10,772	3803	6851
Major criteria: Trough lactate level of <2.5 mmol/L Presence of bile production
Minor criteria: Perfusate pH of >7.30 Stable arterial flow of more than 150 mL/minute and portal flow more than 500 mL/minute Homogeneous liver perfusion with soft consistency of the parenchyma

A viable liver graft has to meet ≥1 major and ≥2 of the minor criteria. All parameters are assessed 120 minutes after commencing the perfusion. To ensure recipient safety and to minimize risks of presence of a preexisting liver disease or irreparable liver damage, only organs meeting the following criteria were considered for the pilot clinical transplant series: maximum donor age of 70 years, CITs of <16 hours for livers from donors after brain death, or <10 hours from DCD, donor WIT (systolic blood pressure <50 mm Hg to aortic perfusion) in DCD organs <60 minutes, absence of hepatitis B, hepatitis C, or human immunodeficiency virus infection, and healthy macroscopic appearance without signs of fibrosis or cirrhosis (Mergental et al.12).

^{a *}

Designates livers that were transplanted.

^†

Values designated with “—” are missing.